Establishment and Applications of Tumor Organoid Models

doi:10.3969/j.issn.1674-5817.2020.06.015

Abstract

Abstract: The organoid is derived from specific stem cells for in vitro three-dimensional culture to form a spatial structure, which keeps similar biological characteristics to the original organ. By this culture technology, the tumor organoids can be established. It well retains the feature in vivo and heterogeneity of the original tumor tissues, displays the advantages of short culture cycle and stable genomes after multiple passages, which compensates the defects of traditional tumor models. These tumor organoids can be used to study the mechanism of tumor development, drug screening and individualized treatment, immunotherapy, liquid biopsy, etc. In this paper, the development history, establishment methods, application prospects and limitations of tumor organoid models are reviewed.

Key words: Organoid, Tumor research, Three-dimensional culture, Individualized treatment

CLC Number:

Q95-33
R73-3

LUO Baohua, ZHANG Yongbin, LIU Xiaoqiu, SHI Changhong. Establishment and Applications of Tumor Organoid Models[J]. Laboratory Animal and Comparative Medicine, 2020, 40(6): 540-546.

Figures/Tables 3

References

[1] Nagle PW, Plukker JTM, Muijs CT, et al.Patient-derived tumor organoids for prediction of cancer treatment response[J]. Semin Cancer Biol, 2018, 53:258-264.
[2] Bleijs M, van de Wetering M, Clevers H. Xenograft and organoid model systems in cancer research[J]. EMBO J, 2019, 38(15):e101654.
[3] Jung J, Seol HS.The generation and application of patient-derived xenograft model for cancer research[J]. Cancer Res Treat, 2018, 50(1):1-10.
[4] Tuveson D.Cancer modeling meets human organoid technology[J]. Science, 2019, 364(6444):952-955.
[5] Lindberg K, Brown ME, Chaves HV, et al.In vitro propagation of human ocular surface epithelial cells for transplantation[J]. Invest Ophthalmol Vis Sci, 1993, 34(9):2672-2679.
[6] Pellegrini G, Traverso CE, Franzi AT, et al.Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium[J]. Lancet, 1997, 349(9057):990-993.
[7] Toshiro S, Robert GV, Hugo JS, et al.Single Lgr5 stem cells buildcrypt-villus structures in vitro without a mesenchymal niche[J]. Nature, 2009, 459(7244):262-265.
[8] Sato T, Stange DE, Ferrante M, et al.Long-term expansionof epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium[J]. Gastroenterology, 2011, 141(5):1762-1772.
[9] van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients[J]. Cell, 2015, 161(4):933-945.
[10] Fujii M, Shimokawa M, Date S, et al.A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis[J]. Cell Stem Cell, 2016, 18(6):827-838.
[11] Gao D, Vela I, Sboner A, et al.Organoid cultures derived from patients with advanced prostate cancer[J]. Cell, 2014, 159(1):176-187.
[12] Mondrinos MJ, Jones PL, Finck CM, et al.Engineering de novo assembly of fetal pulmonary organoids[J]. Tissue Eng Part A, 2014, 20(21/22):2892-2907.
[13] Broutier L, Mastrogiovanni G, Verstegen MM, et al.Human primary liver cancer-derived organoid cultures for disease modeling and drug screening[J]. Nat Med, 2017, 23(12):1424-1435.
[14] Turco MY, Gardner L, Hughes J, et al.Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium[J]. Nat Cell Biol, 2017, 19(5):568-577.
[15] Vlachogiannis G, Hedayat S, Vatsiou A, et al.Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018, 359(6378):920-926.
[16] Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018,172(1/2):373-386.
[17] Lee SH, Hu W, Matulay JT, et al.Tumor evolution and drug response in patient-derived organoid models of bladder cancer[J]. Cell, 2018, 173(2):515-528.
[18] Li X, Francies HE, Secrier M, et al.Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics[J]. Nat Commun, 2018, 9(1):2983.
[19] Kim M, Mun H, Sung CO, et al.Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening[J]. Nat Commun, 2019, 10(1):3991.
[20] Grassi L, Alfonsi R, Francescangeli F, et al.Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases[J]. Cell Death Dis, 2019, 10(3):201.
[21] Kopper O, de Witte CJ, L hmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity[J]. Nat Med, 2019, 25(5):838-849.
[22] Rios AC, Clevers H.Imaging organoids: a bright future ahead[J]. Nat Methods, 2018, 15(1):24-26.
[23] Drost J, van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells[J]. Nature, 2015, 521(7550):43-47.
[24] Nanki K,Toshimitsu K,Takano A,et al.Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis[J]. Cell, 2018, 174(4):856-869.
[25] De Flora S, Crocetti E, Bonanni P, et al.Incidence of infection-associated cancers in Italy and prevention strategies[J]. Epidemiol Prev, 2015, 39(4 Suppl 1):14-20.
[26] Buti L, Ruiz-Puig C, Sangberg D, et al.CagA-ASPP2 complex mediates loss of cell polarity and favors H. pylori colonization of human gastric organoids[J]. Proc Natl Acad Sci U S A, 2020, 117(5):2645-2655.
[27] Ramani S, Crawford SE, Blutt SE.Human organoid cultures: transformative new tools for human virus studies[J]. Curr Opin Virol, 2018, 29:79-86.
[28] Stratton MR, Campbell PJ.The cancer genome[J]. Nature, 2009, 458(7239):719-724.
[29] Huch M, Gehart H, van Boxtel R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver[J]. Cell, 2015, 160(1/2):299-312.
[30] Chio IIC, Jafarnejad SM, Ponz-Sarvise M, et al.NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer[J]. Cell, 2016, 166(4):963-976.
[31] Roerink SF, Sasaki N, Lee-Six H, et al.Intra-tumour diversification in colorectal cancer at the single-cell level[J]. Nature, 2018, 556(7702):457-462.
[32] Rizvi NA, Hellmann MD, Snyder A, et al.Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124-128.
[33] Tuveson D, Clevers H.Cancer modeling meets human organoid technology[J]. Science, 2019, 364(6444):952-955.
[34] Dijkstra KK, Cattaneo CM, Weeber F, et al.Generation of tumor-peactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids[J]. Cell, 2018, 174(6):1586-1598.
[35] Str nen E, Toebes M, Kelderman S, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires[J]. Science, 2016, 352(6291):1337-1341.
[36] Tajima A, Pradhan I, Trucco M.Restoration of thymus function with bioengineered thymus organoids[J]. Curr Stem Cell Rep, 2016, 2(2):128-139.
[37] Merker JD, Oxnard GR, Compton C, et al.Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review[J]. J Clin Oncol, 2018, 36(16):1631-1641.
[38] Praharaj PP, Bhutia SK, Nagrath S, et al.Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine[J]. Biochim Biophys Acta Rev Cancer, 2018, 1869(2):117-127.
[39] Hubert CG, Rivera M, Spangler LC, et al.A three-dimensional organoid culture system derived from human glioblas tomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo[J]. Cancer Res, 2016, 76(8):2465-2477.